Monday, June 15, 2015 7:25:09 AM
- Poster Presentation on June 15, 2015 from 12:30-2:00 p.m. PDT -
SAN FRANCISCO and GENEVA, June 15, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQB:AMBSD), a biotechnology company focused on developing therapeutic and diagnostic products for neurological disorders and orphan indications, announced that data from the Phase 1/2a clinical study of eltoprazine for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID) has been accepted for presentation at the 19th International Congress of Parkinson's Disease and Movement Disorders being held June 14-18, 2015, in San Diego, CA.
Professor Per Svenningsson, M.D., Ph.D., of the Centre for Molecular Medicine at Karolinska Institutet, will present poster number 331 entitled, "Single oral treatment with the 5-HT1A/B agonist, Eltoprazine, counteracts L-dopa-induced dyskinesias in Parkinson's disease: A phase I/IIA, double-blind, randomized, placebo-controlled, dose-finding study," on Monday, June 15, 2015, from 12:30-2:00 p.m. PDT in the Coronado Ballroom of the Manchester Grand Hyatt.
Further, poster number 331 has been selected for a guided poster tour with Professor Svenningsson. Guided Poster Tour 16 entitled, "Parkinson's Disease: Neuropharmacology," will be held at Harbor G, 2nd Level, Harbor Tower from 12:00-3:30 p.m. PDT on Thursday, June 18, 2015.
Eltoprazine is a small-molecule 5-HT1A/1B serotonin receptor agonist, investigational drug candidate, with a well-established safety profile. A Phase 1/2a dose-finding study was conducted with eltoprazine to determine its effect against levodopa-induced dyskinesia, in patients with Parkinson's disease. The double-blind, randomized, placebo-controlled clinical study was led by Professor Svenningsson, Professor Anders Björklund, Ph.D., Faculty of Medicine at Lund University, and Professor Håkan Widner, M.D., Ph.D., Faculty of Medicine at Lund University. The study was partially supported by a grant from The Michael J. Fox Foundation for Parkinson's Research.
Amarantus previously announced that it will commence a multi-center, 60-subject Phase 2b study in individuals with PD-LID before the end of the June 2015. The study will be a double-blind, placebo-controlled, four-way crossover, dose range finding, clinical trial designed to evaluate dose response effect of repeated eltoprazine dosing on safety, tolerability and dyskinesia severity using state-of-the-art rating scales, diaries and motion sensors (ClinicalTrials.gov Identifier: NCT02439125). Pharmacokinetics and pharmacodynamics will also be evaluated. The Company expects to report top-line results from this Phase 2b study in the second quarter of 2016.
About Eltoprazine
FEATURED Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM